These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 31641887

  • 1. Effects of sitagliptin on exercise capacity and hemodynamics in patients with type 2 diabetes mellitus and coronary artery disease.
    Fujimoto N, Moriwaki K, Takeuchi T, Sawai T, Sato Y, Kumagai N, Masuda J, Nakamori S, Ito M, Dohi K.
    Heart Vessels; 2020 May; 35(5):605-613. PubMed ID: 31641887
    [Abstract] [Full Text] [Related]

  • 2. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
    Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, Miyoshi T, Hirata K, Yoshikawa J, Ito H, FESC, for Effect of a DPP-4 inhibitor on left ventricular diastolic dysfunction in patients with type 2 diabetes and diabetic cardiomyopathy (3D) study investigators.
    Cardiovasc Diabetol; 2015 Jun 19; 14():83. PubMed ID: 26084668
    [Abstract] [Full Text] [Related]

  • 3. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
    Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K, PROLOGUE Study Investigators.
    Cardiovasc Diabetol; 2017 May 11; 16(1):63. PubMed ID: 28490337
    [Abstract] [Full Text] [Related]

  • 4. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
    Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, Takagi T, Yunoki K, Miyoshi T, Hirata K, Yoshikawa J, Ito H.
    Cardiovasc Diabetol; 2014 Jul 30; 13():110. PubMed ID: 25074318
    [Abstract] [Full Text] [Related]

  • 5. Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.
    Li B, Luo YR, Tian F, Chen YD, Tian JW, Ding Y, Zhu M, Li JW, Zhang YQ, Shi WM.
    Atherosclerosis; 2020 May 30; 300():10-18. PubMed ID: 32247073
    [Abstract] [Full Text] [Related]

  • 6. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
    Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K.
    J Am Heart Assoc; 2013 Jan 28; 2(1):e003277. PubMed ID: 23525426
    [Abstract] [Full Text] [Related]

  • 7. Effect of Sitagliptin on Coronary Flow Reserve Assessed by Magnetic Resonance Imaging in Type 2 Diabetic Patients With Coronary Artery Disease.
    Moriwaki K, Takeuchi T, Fujimoto N, Sawai T, Sato Y, Kumagai N, Masuda J, Nakamori S, Ishida M, Yamada N, Nakamura M, Sakuma H, Ito M, Dohi K.
    Circ J; 2018 Jul 25; 82(8):2119-2127. PubMed ID: 29760346
    [Abstract] [Full Text] [Related]

  • 8. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
    McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP, Dutka DP.
    Circ Cardiovasc Imaging; 2014 Mar 25; 7(2):274-81. PubMed ID: 24503784
    [Abstract] [Full Text] [Related]

  • 9. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.
    Leung M, Leung DY, Wong VW.
    Diab Vasc Dis Res; 2016 May 25; 13(3):236-43. PubMed ID: 26993495
    [Abstract] [Full Text] [Related]

  • 10. Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design.
    Imazu M, Nakano A, Ito S, Hamasaki T, Kitakaze M, TOPLEVEL investigators and study coordinators.
    Cardiovasc Drugs Ther; 2019 Jun 25; 33(3):363-370. PubMed ID: 30850916
    [Abstract] [Full Text] [Related]

  • 11. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
    Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H.
    Circ J; 2013 Jun 25; 77(5):1337-44. PubMed ID: 23386232
    [Abstract] [Full Text] [Related]

  • 12. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.
    Carbone S, Billingsley HE, Canada JM, Bressi E, Rotelli B, Kadariya D, Dixon DL, Markley R, Trankle CR, Cooke R, Rao K, B Shah K, Medina de Chazal H, Chiabrando JG, Vecchié A, Dell M, L Mihalick V, Bogaev R, Hart L, Van Tassell BW, Arena R, Celi FS, Abbate A.
    Diabetes Metab Res Rev; 2020 Nov 25; 36(8):e3335. PubMed ID: 32415802
    [Abstract] [Full Text] [Related]

  • 13. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
    Fischer-Rasokat U, Honold J, Lochmann D, Wolter S, Liebetrau C, Fichtlscherer S, Möllmann H, Spyridopoulos I, Hamm CW.
    Clin Res Cardiol; 2016 Jun 25; 105(6):527-34. PubMed ID: 26687495
    [Abstract] [Full Text] [Related]

  • 14. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.
    Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, Iida M, Sano H, Tomiyama H, Inoue T, Tanaka A, Murohara T, Node K, PROLOGUE Study Investigators.
    Cardiovasc Diabetol; 2016 Sep 13; 15(1):134. PubMed ID: 27624168
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT).
    Koyama T, Tanaka A, Yoshida H, Oyama JI, Toyoda S, Sakuma M, Inoue T, Otsuka Y, Node K.
    Heart Vessels; 2018 Aug 13; 33(8):958-964. PubMed ID: 29427024
    [Abstract] [Full Text] [Related]

  • 16. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
    Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH.
    J Am Coll Cardiol; 2013 Oct 08; 62(15):1330-8. PubMed ID: 23916925
    [Abstract] [Full Text] [Related]

  • 17. Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study.
    Nozue T, Fukui K, Koyama Y, Fujii H, Kunishima T, Hikita H, Hibi K, Miyazawa A, Michishita I.
    Heart Vessels; 2016 May 08; 31(5):649-54. PubMed ID: 25794984
    [Abstract] [Full Text] [Related]

  • 18. Left ventricular diastolic performance at rest is essential for exercise capacity in patients with non-complicated myocardial infarction.
    Dekleva MN, Mazic SD, Suzic-Lazic JM, Marković-Nikolić NS, Beleslin BD, Stevanović AM, Djelic MN, Arandjelović AM.
    Heart Lung; 2014 May 08; 43(6):500-5. PubMed ID: 24928183
    [Abstract] [Full Text] [Related]

  • 19. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
    Dixon DL, Billingsley HE, Canada JM, Trankle CR, Kadariya D, Cooke R, Hart L, Van Tassell B, Abbate A, Carbone S.
    J Cardiovasc Pharmacol; 2021 Sep 01; 78(3):407-410. PubMed ID: 34132690
    [Abstract] [Full Text] [Related]

  • 20. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
    Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP.
    Circ Cardiovasc Imaging; 2010 Mar 01; 3(2):195-201. PubMed ID: 20075143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.